Whistleblower backlog may start clearing
Lawmakers and not-for-profit groups are pushing the feds to help clear a backlog of some 900 whistleblower lawsuits--and a sizable number of those were filed against drugmakers, the Washington Post reports.
You know the type: Consider the Merck case, which the drugmaker paid $650 to settle; it alleged that the company failed to repay Medicaid rebates. Then there was the $515 million Bristol-Myers Squibb deal, which settled claims of illegal marketing and pricing. Sen. Charles Grassley (R-IA) is among those calling for the Department of Justice to make these investigations a priority. Whether that means we'll see more pharma settlements--well, we'll just have to wait and see.
- read the WP story
Related Articles:
Court reinstates Pfizer whistleblower suit
Whistleblowers allege problems with Wyeth's Prevnar
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

